JP2020528409A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528409A5
JP2020528409A5 JP2020502405A JP2020502405A JP2020528409A5 JP 2020528409 A5 JP2020528409 A5 JP 2020528409A5 JP 2020502405 A JP2020502405 A JP 2020502405A JP 2020502405 A JP2020502405 A JP 2020502405A JP 2020528409 A5 JP2020528409 A5 JP 2020528409A5
Authority
JP
Japan
Prior art keywords
dosage form
unit dosage
single unit
subject
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020502405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528409A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042937 external-priority patent/WO2019018676A1/en
Publication of JP2020528409A publication Critical patent/JP2020528409A/ja
Publication of JP2020528409A5 publication Critical patent/JP2020528409A5/ja
Priority to JP2023093929A priority Critical patent/JP2023123523A/ja
Withdrawn legal-status Critical Current

Links

JP2020502405A 2017-07-20 2018-07-19 Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物 Withdrawn JP2020528409A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023093929A JP2023123523A (ja) 2017-07-20 2023-06-07 Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762534885P 2017-07-20 2017-07-20
US62/534,885 2017-07-20
US201762571384P 2017-10-12 2017-10-12
US62/571,384 2017-10-12
US201862623174P 2018-01-29 2018-01-29
US62/623,174 2018-01-29
US201862665339P 2018-05-01 2018-05-01
US62/665,339 2018-05-01
PCT/US2018/042937 WO2019018676A1 (en) 2017-07-20 2018-07-19 COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093929A Division JP2023123523A (ja) 2017-07-20 2023-06-07 Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物

Publications (2)

Publication Number Publication Date
JP2020528409A JP2020528409A (ja) 2020-09-24
JP2020528409A5 true JP2020528409A5 (enExample) 2021-08-26

Family

ID=63168494

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502405A Withdrawn JP2020528409A (ja) 2017-07-20 2018-07-19 Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物
JP2023093929A Pending JP2023123523A (ja) 2017-07-20 2023-06-07 Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023093929A Pending JP2023123523A (ja) 2017-07-20 2023-06-07 Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物

Country Status (10)

Country Link
US (1) US10786518B2 (enExample)
EP (2) EP3654951A1 (enExample)
JP (2) JP2020528409A (enExample)
AU (1) AU2018304373B2 (enExample)
BR (1) BR112020000842A2 (enExample)
CA (1) CA3070713A1 (enExample)
CL (1) CL2020000136A1 (enExample)
MA (1) MA49635A (enExample)
MX (1) MX2020000694A (enExample)
WO (1) WO2019018676A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210290590A1 (en) * 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv
CN111419811A (zh) * 2020-05-20 2020-07-17 北京华睿鼎信科技有限公司 一种富马酸替诺福韦艾拉酚胺组合物
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2920110A (en) 1952-12-11 1960-01-05 Ethyl Corp Preparation of meta dichloro- and dibromo-benzenes
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
SI2729128T1 (sl) 2011-07-07 2016-11-30 Janssen Sciences Ireland Uc Formulacije darunavirja
EP2729130B1 (en) * 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
AU2015373104B2 (en) * 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Similar Documents

Publication Publication Date Title
JP2022160589A (ja) Ｈｉｖを治療するためのトール様受容体の調節因子
AU2015318061B2 (en) Solid forms of a toll-like receptor modulator
JP2015038149A5 (enExample)
JP2018527366A (ja) ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
JP2022009683A (ja) テノホビルアラフェナミドの結晶形態
US20160067255A1 (en) Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
RU2015110699A (ru) Фармацевтическая антиретровирусная композиция
JP2020528409A5 (enExample)
AU2016330895A1 (en) Compounds and combinations for the treatment of HIV
JP7313438B2 (ja) Ｈｉｖの予防のためのインテグラーゼ阻害剤
EP3700573A1 (en) Methods of treating patients co-infected with a virus and tuberculosis
JP2020527570A (ja) 組み合わせ薬物療法
WO2018005909A1 (en) Combinations and uses and treatments thereof
WO2017205585A1 (en) Combinations and uses treatments thereof
JP2022538338A5 (enExample)
JP2022538449A5 (enExample)
EP3664895A1 (en) Combinations and uses and treatments thereof
CA3113011C (en) Integrase inhibitors for the prevention of hiv
WO2018051250A1 (en) Combination comprising tenofovir alafenamide, bictegravir and 3tc
WO2018042332A1 (en) Combinations and uses and treatments thereof
WO2018044853A1 (en) Combinations and uses and treatments thereof
RU2022102380A (ru) Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина
Sidhu et al. Pharmacokinetic modeling predicts different IgG exposures using different IVIG-SCIG dose conversion factors in patients with primary immune deficiency
HK40048893A (en) Integrase inhibitors for the prevention of hiv
US20200246351A1 (en) Combinations and uses and treatments thereof